BioSante Pharmaceuticals, Inc. has completed the merger with ANI Pharmaceuticals. Arthur S. Przybyl, BioSante’s new president and chief executive officer said, “This merger is the catalyst for potential future growth. We now have a strong balance sheet with over $10 million in cash and no debt. We expect to utilize the incremental cash available to us as a result of this merger to accelerate our product development efforts and for potential accretive acquisitions. In addition, we exp...